Loading Events

2022 Cholesterol Summit

May 12, 2022

9:00 am CDT -3:00 pm CDT

Join this free one-day virtual summit to learn strategies to close the gap in optimal cholesterol management by enhancing and empowering healthcare professionals, like you!  Tune in to hear from thought leaders across the country as they share strategies to understand and apply evidence-based National Guidelines for the management of dyslipidemia and the primary and secondary prevention of ASCVD.

This is a non-CE educational event.  While there are no continuing education credits associated with it, it is high-quality content from content experts and nationally recognized thought leaders.


Join the webinar with the following links.

9:00 AM CTWelcome
9:15 AM CTLipoprotein(a) and ASCVD Risk
Marlys Koschinsky PhD, FAHA, FNLA, FCAHS, FACC, OOnt
10:00 AM CTHomozygous Familial Hypercholesterolemia (HoFH): Patient Perspectives
Allison Jameson, Patient Advocate
10:45 AM CTSpeaker Panel
11:00 AM CTThe Role of Non-Statin Therapies in Optimal Cholesterol Management
Gina Lundberg, MD
11:45 AM CTProduct Theater by Esperion
A Next Step in LDL-C–Lowering Therapy: Oral Nonstatin Therapies
Payal Kohli, MD
12:30 PM CTBreak
12:45 PM CTLunch & Learn: Overcoming Provider and Patient Inertia
Marla Cohen, Patient Advocate
1:30 PM CTImproving Adherence to Cholesterol Lowering Therapies
2:15 PM CTSpeaker Panel
2:30 PM CTTransitioning from Acute to Chronic Lipid Management
Joe Saseen, PharmD, FNLA, CLS
3:15 PM CTWrap-up

Learning Objectives

Lipoprotein(a) and ASCVD Risk
  1. Describe Lipoprotein(a) and measurement practices
  2.  Explore the link between Lipoprotein(a), ASCVD risk, and family history
  3. Discuss current and future treatments for Lipoprotein(a)
  4. Review a case study on the explanation of elevated Lipoprotein(a) risk and initial diagnosis
Homozygous Familial Hypercholesterolemia (HoFH): Patient Perspectives
  1. Describe HoFH including etiology, prevalence, signs, and symptoms
  2. Hear from patients and families as they discuss the effects of HoFH
  3. Explore shared decision making in the testing and treatment of HoFH
The Role of Non-Statin Therapies in Optimal Cholesterol Management
  1. Explore residual ASCVD risks and solutions for closing the treatment gap
  2. Explain statin side effects and intolerance
  3. Explore the undertreatment risk in Familial Hyperlipidemia
  4. Identify strategies to increase compliance to medication regimens
Transitioning from Acute to Chronic Lipid Management
  1. Discuss patient and family education techniques taking into consideration the social detriments of health present and the patient perspective
  2. Discuss the medications and health conditions that can increase cholesterol
  3. Review discharge planning considerations to overcome barriers to treatment adherence
Overcoming Provider and Patient Inertia
  1. Discuss patient-centric guideline translation
  2. Explain the benefits of a team-based approach to patient care
  3. Explore enhancing care by using the electronic health record and decision support
Improving Adherence to Cholesterol-Lowering Therapies
  1.  Explore patient-centered care and joint decision-making
  2. Explore health disparities and cultural concerns present in medication adherence
  3. Discuss resources to overcome barriers to adherence including the cost of medications and complex treatment regimens

Thank you for the independent educational grants from Amgen Inc., Esperion Therapeutics, Inc., Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals, Inc.